Claims

1. A compound of formula (I):



(I)

wherein:

R^1 represents substituted or unsubstituted heterocyclyl;

Y represents $-(CR_{na}R_{nb})_n-$;

R_{na} and R_{nb} are each independently hydrogen or C_{1-6}alkyl;

n is an integer from 1 to 5;

R^2 represents unsubstituted or substituted aryl or unsubstituted or substituted heteroaryl;

R^3 represents hydrogen or C_{1-6}alkyl;

and salts and solvates thereof;

with the proviso that the following compound is excluded;

N-{[4-(3,4-dichlorobenzyl)morpholin-2-yl]methyl}-2-(1,1-dioxidothiomorpholin-4-yl)acetamide.

2. A compound of formula (I) according to claim 1 wherein R^1 is unsubstituted or substituted pyrandionyl, unsubstituted or substituted uracilyl, unsubstituted or substituted piperidinyl, unsubstituted or substituted hydantoinyl, or unsubstituted or substituted piperazinyl.

3. A compound of formula (I) according to claim 1 or claim 2 wherein R^1 is pyran-3,4-dion-6-yl, 4-methyluracil-6-yl, 1-(methylcarbonyl)piperidin-4-yl, piperidin-4-yl, 1-(aminocarbonyl)piperidin-4-yl, 1-(cyclopropylaminocarbonyl)piperidin-4-yl, 1-(*tert*-butoxycarbonyl)piperidin-4-yl, 4-(methanesulphonylamino)piperidin-1-yl, 4-(methylcarbonylamino)piperidin-1-yl, 1-(cyclopropylcarbonyl)piperidin-4-yl, 1-(ethylaminocarbonyl)piperidin-4-yl, 1-(*iso*-propylaminocarbonyl)piperidin-4-yl, 1-(*iso*-propylcarbonyl)piperidin-4-yl, 1-(ethoxycarbonyl)piperidin-4-yl, 1-(methoxycarbonyl)piperidin-4-yl, 1-(ethylcarbonyl)piperidin-4-yl, 1-(ethanesulphonyl)piperidin-4-yl, 1-(methylaminocarbonyl)piperidin-4-yl, 1-(methanesulphonyl)piperidin-4-yl, 1-

((diethyl)aminocarbonyl)piperidin-4-yl,  ,  ,  ,  ,  ,  , and 

4. A compound of formula (I) according to any one of the preceding claims wherein R_{na} and R_{nb} are both hydrogen.

5. A compound of formula (I) according to any one of the preceding claims wherein n is 1 or 2.

6. A compound of formula (I) according to any one of the preceding claims wherein R^3 is hydrogen.

7. A compound of formula (I) according to any one of the preceding claims wherein R^2 is unsubstituted or substituted phenyl or unsubstituted or substituted thiophenyl.

8. A compound of formula (I) according to any one of the preceding claims wherein R^2 is phenyl substituted with chloro.

9. A compound of formula (I) according to any one of the preceding claims wherein R^2 is 3,4-dichlorophenyl.

10. A compound of formula (I) according to claim 1 selected from the Examples.

11. A compound of formula (I) according to claim 10 selected from Examples 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 14, 15, 19, and 20.

12. A compound of formula (I) according to claim 10 selected from Examples 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, and 11.

13. A compound of formula (I) according to claim 10 selected from Examples 1, 2, and 3.

14. A process for the preparation of a compound of formula (I) as defined in claim 1 which process comprises the reaction of a compound of formula (II) with a compound of formula (III);


(II)


(III)

wherein;

R^1, Y, R^3, and R^2 are as hereinbefore defined for formula (I) in claim 1, in the presence of a base and an activating agent and optionally a peptide coupling agent, and thereafter, if required, carrying out one or more of the following optional steps:

(i) converting a compound of formula (I) to a further compound of formula (I);

(ii) removing any necessary protecting group;

(iii) preparing a salt or solvate of the compound so formed.

15. A process for the preparation of a compound of formula (I) as defined in claim 1 wherein Y is $-CH_2-$ and R^1 is an unsubstituted or substituted N-linked heterocyclyl group i.e. a compound of formula (XI)


(XI)

which process comprises the reaction of a compound of formula (XII) with a compound of formula (XIII);



(XII)



(XIII)

wherein (XII) is an unsubstituted or substituted heterocyclyl group, L^2 is a leaving group, and R^3 and R^2 are as hereinbefore defined for formula (I) in claim 1, and thereafter, if required, carrying out one or more of the following optional steps:

(i) converting a compound of formula (I) to a further compound of formula (I);

(ii) removing any necessary protecting group;

(iii) preparing a salt or solvate of the compound so formed.

16. A compound of formula (IIIBR)



wherein A is a protected amino group and R^2 is as defined for formula (I) in claim 1.

17. A compound of formula (IIIBE)



wherein A is a protected amino group and R^2 is as defined for formula (I) in claim 1.

18. A compound of formula (XIII)



wherein L^2 is a leaving group and R^2 and R^3 are as defined for formula (I) in claim 1.

19. A compound of formula (I) as defined in claim 1 or a physiologically acceptable salt or solvate thereof for use as an active therapeutic agent.

20. A compound of formula (I) as defined in claim 1, or a physiologically acceptable salt or solvate thereof, for use in the treatment of inflammatory conditions, e.g. asthma or rhinitis.

21. Use of a compound of formula (I) as defined in claim 1 or a physiologically acceptable salt or solvate thereof for the manufacture of a medicament for the treatment of inflammatory conditions, eg. asthma or rhinitis.

22. A method for the treatment of a human or animal subject suffering from or susceptible to an inflammatory condition e.g. asthma or rhinitis, which method comprises administering an effective amount of a compound of formula (I) as defined in claim 1 or a physiologically acceptable salt or solvate thereof.

23. A pharmaceutical composition comprising a compound of formula (I) as defined in claim 1, or a physiologically acceptable salt or solvate thereof, and optionally one or more physiologically acceptable diluents or carriers.